KANTAR HEALTH BLOG

kh_blog_hero_1600px
  • The "Science" and "Art" behind a Great Segmentation Study

    by Richard Goosey  |  Mar 24, 2017
    Properly identifying market segments is an integral part of a launch excellence program. In the post, Richard Goosey reviews the “art and science” of market segmentation in healthcare and the need to activate and embed the segmentation among all stakeholders to achieve optimal success.
  • New research by Kantar Health, developed in South Korea has found that Patient Blog studies enable a much closer look into the real lives of patients than ever before and serve as a more effective means to understanding the increasingly important roles patients play in healthcare decision making.
  • Physician interest is declining for participating in market research surveys. Kantar Health has fully embraced the task of improving respondent engagement in our studies and we're proud to talk about two recent successes.
  • World Cancer Day: we can, I can!

    by Otávio Clark  |  Feb 3, 2017
    On February 4 we observe World Cancer Day, a day created by the Union for International Cancer Control (UICC) aimed at making people all around the world talk about the disease and take actions that can help reduce the impact and weight of diagnosis in families.
  • Opdivo Making Strides in Advanced Hepatocellular Carcinoma

    by Stephanie Hawthorne  |  Jan 23, 2017
    Oncology Conference Insight: ASCO GI 2017 --- It is an exciting time for patients and their doctors fighting advanced hepatocellular carcinoma (HCC). In mid-2016 the HCC community witnessed the first randomized trial to successfully improve survival outcomes in Nexavar® (sorafenib, Onyx/Amgen/Bayer)-pretreated HCC when the multikinase inhibitor Stivarga® (regorafenib, Bayer) demonstrated a 38% reduction in the risk of death compared with placebo in the Phase III RESOURCE trial.